sábado, 23 de octubre de 2021

SARS-CoV-2 anti-nucleocapsid antibodies reduce risk of reinfection for at least eight months

SARS-CoV-2 anti-nucleocapsid antibodies reduce risk of reinfection for at least eight months

No hay comentarios:

Publicar un comentario